More recently, studies in chronic lymphocytic leukemia (CLL) indicated that patient-derived T cells treated with NAE inhibitors, showed significant differential expression of NF‐κB‐regulated genes and downregulated IL-2 expression/signalling during activation [59]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.